The First Berberine-Based Inhibitors of Tyrosyl-DNA Phosphodiesterase 1 (Tdp1), an Important DNA Repair Enzyme.
Antineoplastic Agents, Phytogenic
/ chemical synthesis
Berberine
/ analogs & derivatives
Binding Sites
DNA Repair
/ drug effects
Drug Combinations
Drug Design
Drug Synergism
HeLa Cells
Humans
Inhibitory Concentration 50
Molecular Docking Simulation
Phosphodiesterase Inhibitors
/ chemical synthesis
Phosphoric Diester Hydrolases
/ chemistry
Protein Binding
Protein Conformation
Structure-Activity Relationship
Topoisomerase I Inhibitors
/ chemistry
Topotecan
/ chemistry
DNA repair enzyme
SAR
Tdp1 inhibitor
berberine
cancer
molecular modeling
tetrahydroberberine
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
28 Sep 2020
28 Sep 2020
Historique:
received:
31
08
2020
revised:
22
09
2020
accepted:
26
09
2020
entrez:
1
10
2020
pubmed:
2
10
2020
medline:
26
2
2021
Statut:
epublish
Résumé
A series of berberine and tetrahydroberberine sulfonate derivatives were prepared and tested against the tyrosyl-DNA phosphodiesterase 1 (Tdp1) DNA-repair enzyme. The berberine derivatives inhibit the Tdp1 enzyme in the low micromolar range; this is the first reported berberine based Tdp1 inhibitor. A structure-activity relationship analysis revealed the importance of bromine substitution in the 12-position on the tetrahydroberberine scaffold. Furthermore, it was shown that the addition of a sulfonate group containing a polyfluoroaromatic moiety at position 9 leads to increased potency, while most of the derivatives containing an alkyl fragment at the same position were not active. According to the molecular modeling, the bromine atom in position 12 forms a hydrogen bond to histidine 493, a key catalytic residue. The cytotoxic effect of topotecan, a clinically important topoisomerase 1 inhibitor, was doubled in the cervical cancer HeLa cell line by derivatives 11g and 12g; both displayed low toxicity without topotecan. Derivatives 11g and 12g can therefore be used for further development to sensitize the action of clinically relevant Topo1 inhibitors.
Identifiants
pubmed: 32998385
pii: ijms21197162
doi: 10.3390/ijms21197162
pmc: PMC7582571
pii:
doi:
Substances chimiques
Antineoplastic Agents, Phytogenic
0
Drug Combinations
0
Phosphodiesterase Inhibitors
0
Topoisomerase I Inhibitors
0
Berberine
0I8Y3P32UF
Topotecan
7M7YKX2N15
Phosphoric Diester Hydrolases
EC 3.1.4.-
TDP1 protein, human
EC 3.1.4.-
canadine
V2SSH085X8
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Russian Science Foundation
ID : 19-13-00040
Références
Bioorg Med Chem. 2015 May 1;23(9):2044-52
pubmed: 25819333
Expert Opin Ther Pat. 2011 Sep;21(9):1285-92
pubmed: 21843105
Bioorg Med Chem Lett. 2017 Feb 15;27(4):701-707
pubmed: 28073672
Proteins. 2005 Nov 1;61(2):272-87
pubmed: 16106379
Mol Inform. 2012 Dec;31(11-12):847-55
pubmed: 27476738
Bioorg Med Chem. 2016 Nov 1;24(21):5017-5027
pubmed: 27687971
Bioorg Chem. 2018 Feb;76:392-399
pubmed: 29248742
Int J Mol Sci. 2019 Dec 23;21(1):
pubmed: 31878088
Biochem Pharmacol. 2012 Jan 1;83(1):27-36
pubmed: 21978643
DNA Repair (Amst). 2014 Jul;19:114-29
pubmed: 24856239
Cancer Drug Resist. 2019;2:1153-1163
pubmed: 31875206
Sci Rep. 2016 Apr 22;6:24748
pubmed: 27103062
Chem Biol. 2010 May 28;17(5):421-33
pubmed: 20534341
Pharmacol Res. 2019 Oct;148:104398
pubmed: 31415916
Nat Struct Biol. 2003 Dec;10(12):980
pubmed: 14634627
Org Biomol Chem. 2020 Jul 15;18(27):5130-5136
pubmed: 32379263
Drug Metab Rev. 2014 Nov;46(4):494-507
pubmed: 25327705
Molecules. 2019 Oct 15;24(20):
pubmed: 31619021
Int J Mol Sci. 2020 Jul 12;21(14):
pubmed: 32664667
Mol Inform. 2019 Mar;38(3):e1800068
pubmed: 30345657
Molecules. 2020 Jul 31;25(15):
pubmed: 32751997
J Chem Inf Model. 2009 Jan;49(1):84-96
pubmed: 19125657
Int J Endocrinol. 2015;2015:905749
pubmed: 25861268
J Mol Biol. 1997 Apr 4;267(3):727-48
pubmed: 9126849
Bioorg Med Chem. 2016 Nov 1;24(21):5573-5581
pubmed: 27658793
Nucleic Acids Res. 2000 Jan 1;28(1):235-42
pubmed: 10592235
Int J Clin Exp Pathol. 2015 May 01;8(5):5217-23
pubmed: 26191220
J Med Chem. 2018 Nov 21;61(22):9908-9930
pubmed: 30336023
J Comput Aided Mol Des. 1997 Sep;11(5):425-45
pubmed: 9385547
J Nat Prod. 2016 Nov 23;79(11):2961-2967
pubmed: 27933897
J Med Food. 2005 Winter;8(4):454-61
pubmed: 16379555
Proteins. 2003 Sep 1;52(4):609-23
pubmed: 12910460
F1000Res. 2019 Sep 30;8:
pubmed: 31602296
Cancer Manag Res. 2019 May 10;11:4371-4390
pubmed: 31191001
Nucleic Acids Res. 2019 Nov 4;47(19):10134-10150
pubmed: 31199869
Eur J Med Chem. 2019 Jan 1;161:581-593
pubmed: 30396105
Int J Nanomedicine. 2011;6:1773-7
pubmed: 21931477
Int J Mol Sci. 2020 Jul 11;21(14):
pubmed: 32664581
Molecules. 2018 Mar 17;23(3):
pubmed: 29562592